• Je něco špatně v tomto záznamu ?

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients

SP. McAdoo, A. Tanna, Z. Hrušková, L. Holm, M. Weiner, N. Arulkumaran, A. Kang, V. Satrapová, J. Levy, S. Ohlsson, V. Tesar, M. Segelmark, CD. Pusey,

. 2017 ; 92 (3) : 693-702. [pub] 20170512

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025021

Co-presentation with both ANCA and anti-GBM antibodies is thought to be relatively rare. Current studies of such 'double-positive' cases report small numbers and variable outcomes. To study this further we retrospectively analyzed clinical features and long-term outcomes of a large cohort of 568 contemporary patients with ANCA-associated vasculitis, 41 patients with anti-GBM disease, and 37 double-positive patients with ANCA and anti-GBM disease from four European centers. Double-positive patients shared characteristics of ANCA-associated vasculitis (AAV), such as older age distribution and longer symptom duration before diagnosis, and features of anti-GBM disease, such as severe renal disease and high frequency of lung hemorrhage at presentation. Despite having more evidence of chronic injury on renal biopsy compared to patients with anti-GBM disease, double-positive patients had a greater tendency to recover from being dialysis-dependent after treatment and had intermediate long-term renal survival compared to the single-positive patients. However, overall patient survival was similar in all three groups. Predictors of poor patient survival included advanced age, severe renal failure, and lung hemorrhage at presentation. No single-positive anti-GBM patients experienced disease relapse, whereas approximately half of surviving patients with AAV and double-positive patients had recurrent disease during a median follow-up of 4.8 years. Thus, double-positive patients have a truly hybrid disease phenotype, requiring aggressive early treatment for anti-GBM disease, and careful long-term follow-up and consideration for maintenance immunosuppression for AAV. Since double-positivity appears common, further work is required to define the underlying mechanisms of this association and define optimum treatment strategies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025021
003      
CZ-PrNML
005      
20180717084858.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.kint.2017.03.014 $2 doi
035    __
$a (PubMed)28506760
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a McAdoo, Stephen P $u Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK. Electronic address: s.mcadoo@imperial.ac.uk.
245    10
$a Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients / $c SP. McAdoo, A. Tanna, Z. Hrušková, L. Holm, M. Weiner, N. Arulkumaran, A. Kang, V. Satrapová, J. Levy, S. Ohlsson, V. Tesar, M. Segelmark, CD. Pusey,
520    9_
$a Co-presentation with both ANCA and anti-GBM antibodies is thought to be relatively rare. Current studies of such 'double-positive' cases report small numbers and variable outcomes. To study this further we retrospectively analyzed clinical features and long-term outcomes of a large cohort of 568 contemporary patients with ANCA-associated vasculitis, 41 patients with anti-GBM disease, and 37 double-positive patients with ANCA and anti-GBM disease from four European centers. Double-positive patients shared characteristics of ANCA-associated vasculitis (AAV), such as older age distribution and longer symptom duration before diagnosis, and features of anti-GBM disease, such as severe renal disease and high frequency of lung hemorrhage at presentation. Despite having more evidence of chronic injury on renal biopsy compared to patients with anti-GBM disease, double-positive patients had a greater tendency to recover from being dialysis-dependent after treatment and had intermediate long-term renal survival compared to the single-positive patients. However, overall patient survival was similar in all three groups. Predictors of poor patient survival included advanced age, severe renal failure, and lung hemorrhage at presentation. No single-positive anti-GBM patients experienced disease relapse, whereas approximately half of surviving patients with AAV and double-positive patients had recurrent disease during a median follow-up of 4.8 years. Thus, double-positive patients have a truly hybrid disease phenotype, requiring aggressive early treatment for anti-GBM disease, and careful long-term follow-up and consideration for maintenance immunosuppression for AAV. Since double-positivity appears common, further work is required to define the underlying mechanisms of this association and define optimum treatment strategies.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antirenální glomerulonefritida $x krev $x imunologie $x mortalita $x terapie $7 D019867
650    _2
$a ANCA-asociované vaskulitidy $x krev $x imunologie $x mortalita $x terapie $7 D056648
650    _2
$a protilátky proti cytoplazmě neutrofilů $x krev $7 D019268
650    _2
$a autoprotilátky $x krev $7 D001323
650    _2
$a dítě $7 D002648
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a krvácení $x imunologie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a ledviny $x imunologie $x patologie $7 D007668
650    _2
$a chronické selhání ledvin $x krev $x imunologie $x mortalita $x terapie $7 D007676
650    _2
$a plicní nemoci $x imunologie $7 D008171
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a recidiva $7 D012008
650    _2
$a dialýza ledvin $7 D006435
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Tanna, Anisha $u Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK.
700    1_
$a Hrušková, Zdenka $u Department of Nephrology, General University Hospital, Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Holm, Lisa $u Department of Nephrology and Transplantation, Skånes University Hospital, Lund, Sweden.
700    1_
$a Weiner, Maria $u Department of Nephrology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
700    1_
$a Arulkumaran, Nishkantha $u Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK.
700    1_
$a Kang, Amy $u Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK.
700    1_
$a Satrapová, Veronika $u Department of Nephrology, General University Hospital, Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Levy, Jeremy $u Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK.
700    1_
$a Ohlsson, Sophie $u Department of Nephrology and Transplantation, Skånes University Hospital, Lund, Sweden.
700    1_
$a Tesar, Vladimir $u Department of Nephrology, General University Hospital, Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Segelmark, Mårten $u Department of Nephrology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
700    1_
$a Pusey, Charles D $u Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK.
773    0_
$w MED00010141 $t Kidney international $x 1523-1755 $g Roč. 92, č. 3 (2017), s. 693-702
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28506760 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180717085157 $b ABA008
999    __
$a ok $b bmc $g 1317152 $s 1021942
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 92 $c 3 $d 693-702 $e 20170512 $i 1523-1755 $m Kidney international $n Kidney Int $x MED00010141
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace